| Carvedilol | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | |
| Carvedilol | hsa00052 | Galactose metabolism | 1.06E-03 | 2 | P06280, O43451 | GLA, MGAM | More | |
| Carvedilol | hsa00071 | Fatty acid degradation | 2.52E-02 | 3 | O75521, P11766, P33121 | ECI2, ADH5, ACSL1 | More | |
| Carvedilol | hsa00190 | Oxidative phosphorylation | 2.29E-02 | 2 | Q16718, O14521 | NDUFA5, SDHD | More | |
| Carvedilol | hsa00500 | Starch and sucrose metabolism | 7.59E-07 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | |
| Carvedilol | hsa00630 | Glyoxylate and dicarboxylate metabolism | 4.12E-03 | 2 | P40925, P15104 | MDH1, GLUL | More | |
| Carvedilol | hsa00730 | Thiamine metabolism | 5.31E-07 | 3 | Q9Y6K8, P05186, P24666 | AK5, ALPL, ACP1 | More | |
| Carvedilol | hsa00760 | Nicotinate and nicotinamide metabolism | 3.52E-02 | 1 | P21589 | NT5E | More | |
| Carvedilol | hsa00770 | Pantothenate and CoA biosynthesis | 5.15E-04 | 3 | O95498, O95497, Q9NRN7 | VNN2, VNN1, AASDHPPT | More | |
| Carvedilol | hsa00830 | Retinol metabolism | 3.19E-02 | 1 | P00325 | ADH1B | More | |
| Carvedilol | hsa00970 | Aminoacyl-tRNA biosynthesis | 2.77E-04 | 4 | O95363, P54136, P14868, Q15046 | FARS2, RARS1, DARS, KARS | More | |
| Carvedilol | hsa00983 | Drug metabolism - other enzymes | 2.44E-02 | 2 | P32320, P05164 | CDA, MPO | More | |
| Carvedilol | hsa01100 | Metabolic pathways | 3.52E-02 | 23 | P05089, O95455, P21953, P32320, P11766, P06280, Q16875, O43286, O43451, P05186, P24666, Q9HCC0, P33121, Q08477, P15907, Q9UNP4, P37837, P32321, Q9BPW9, Q9UHY7, P43490, P46976, P06737 | ARG1, TGDS, BCKDHB, CDA, ADH5, GLA, PFKFB3, B4GALT5, MGAM, ALPL, ACP1, MCCC2, ACSL1, CYP4F3, ST6GAL1, ST3GAL5, TALDO1, DCTD, DHRS9, ENOPH1, PBEF1, GYG1, PYGL | More | |
| Carvedilol | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | |
| Carvedilol | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | |
| Carvedilol | hsa02010 | ABC transporters | 2.29E-02 | 2 | P45844, P08183 | ABCG1, ABCB1 | More | |
| Carvedilol | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | |
| Carvedilol | hsa03320 | PPAR signaling pathway | 4.33E-02 | 2 | Q6PCB7, Q9UNU6 | SLC27A1, CYP8B1 | More | |
| Carvedilol | hsa04060 | Cytokine-cytokine receptor interaction | 4.71E-02 | 2 | P78552, O75509 | IL13RA1, TNFRSF21 | More | |
| Carvedilol | hsa04071 | Sphingolipid signaling pathway | 6.08E-04 | 5 | P21453, Q9H228, P01375, Q13362, Q9UQC2 | S1PR1, EDG8, TNF, PPP2R5C, GAB2 | More | |
| Carvedilol | hsa04072 | Phospholipase D signaling pathway | 9.70E-03 | 2 | Q92529, Q14344 | SHC3, GNA13 | More | |
| Carvedilol | hsa04080 | Neuroactive ligand-receptor interaction | 1.97E-02 | 5 | P28472, P21453, Q9H228, P21730, P07550 | GABRB3, S1PR1, EDG8, C5AR1, ADRB2 | More | |
| Carvedilol | hsa04114 | Oocyte meiosis | 6.23E-03 | 5 | Q9Y6D9, P51812, Q02750, P16298, Q17RY0 | MAD1L1, RPS6KA3, MAP2K1, PPP3CB, CPEB4 | More | |
| Carvedilol | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | |
| Carvedilol | hsa04140 | Autophagy - animal | 1.95E-02 | 3 | Q96RR4, O75460, Q8TEV9 | CAMKK2, ERN1, SMCR8 | More | |
| Carvedilol | hsa04150 | mTOR signaling pathway | 2.23E-02 | 3 | P42338, Q13322, P49841 | PIK3CB, GRB10, GSK3B | More | |
| Carvedilol | hsa04210 | Apoptosis | 3.58E-02 | 4 | O76075, P01375, Q9NR28, Q16548 | DFFB, TNF, DIABLO, BCL2A1 | More | |
| Carvedilol | hsa04213 | Longevity regulating pathway - multiple species | 2.85E-02 | 2 | Q9Y4H2, Q13547 | IRS2, HDAC1 | More | |
| Carvedilol | hsa04217 | Necroptosis | 2.34E-02 | 4 | P01375, P48023, Q14765, Q99878 | TNF, FASLG, STAT4, H2AC14 | More | |
| Carvedilol | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.95E-02 | 4 | P07550, P22694, P18848, Q13362 | ADRB2, PRKACB, ATF4, PPP2R5C | More | |
| Carvedilol | hsa04340 | Hedgehog signaling pathway | 3.32E-02 | 2 | P49841, P22694 | GSK3B, PRKACB | More | |
| Carvedilol | hsa04370 | VEGF signaling pathway | 3.06E-03 | 3 | P16298, Q05397, Q02750 | PPP3CB, PTK2, MAP2K1 | More | |
| Carvedilol | hsa04380 | Osteoclast differentiation | 1.39E-03 | 8 | Q9UQC2, Q16539, P06239, P42338, P14778, O75015, P01375, Q8N149 | GAB2, MAPK14, LCK, PIK3CB, IL1R1, FCGR3B, TNF, LILRA2 | More | |
| Carvedilol | hsa04392 | Hippo signaling pathway - multiple species | 3.01E-02 | 1 | Q6V0I7 | FAT4 | More | |
| Carvedilol | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 4.73E-02 | 3 | Q13873, Q02750, Q86SE9 | BMPR2, MAP2K1, PCGF5 | More | |
| Carvedilol | hsa04612 | Antigen processing and presentation | 1.07E-03 | 6 | Q14953, P26715, P26717, Q13241, P01732, P01375 | KIR2DS5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | |
| Carvedilol | hsa04613 | Neutrophil extracellular trap formation | 3.76E-04 | 10 | P11215, Q13547, P04908, Q93077, P58876, Q16778, O60814, P68431, O43315, Q16539 | ITGAM, HDAC1, H2AC4; H2AC8, HIST1H2AC, H2BC5, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, AQP9, MAPK14 | More | |
| Carvedilol | hsa04621 | NOD-like receptor signaling pathway | 1.93E-02 | 8 | Q16539, P10599, Q9H1Y0, P43490, O00463, P01375, P09341, P12838 | MAPK14, TXN, ATG5, PBEF1, TRAF5, TNF, CXCL1, DEFA4 | More | |
| Carvedilol | hsa04625 | C-type lectin receptor signaling pathway | 3.87E-02 | 4 | Q9ULY5, P20749, P01375, Q16539 | CLEC4E, BCL3, TNF, MAPK14 | More | |
| Carvedilol | hsa04650 | Natural killer cell mediated cytotoxicity | 5.56E-05 | 10 | P16298, P50591, P01375, P20963, Q02750, Q13241, P26718, P26717, Q14953, P26715 | PPP3CB, TNFSF10, TNF, CD247, MAP2K1, KLRD1, KLRK1, KLRC2, KIR2DS5, KLRC1 | More | |
| Carvedilol | hsa04657 | IL-17 signaling pathway | 3.50E-06 | 8 | O00463, Q16539, P49841, P09341, P19875, P14780, P80188, P01375 | TRAF5, MAPK14, GSK3B, CXCL1, CXCL2, MMP9, LCN2, TNF | More | |
| Carvedilol | hsa04659 | Th17 cell differentiation | 4.12E-02 | 4 | P06239, P14784, P14778, P07766 | LCK, IL2RB, IL1R1, CD3E | More | |
| Carvedilol | hsa04662 | B cell receptor signaling pathway | 7.25E-03 | 4 | P49841, P42338, P21854, Q8N149 | GSK3B, PIK3CB, CD72, LILRA2 | More | |
| Carvedilol | hsa04664 | Fc epsilon RI signaling pathway | 3.98E-02 | 3 | P01375, Q16539, Q9UQC2 | TNF, MAPK14, GAB2 | More | |
| Carvedilol | hsa04668 | TNF signaling pathway | 2.12E-03 | 7 | P01375, O00463, Q16539, P18848, P19875, P20749, P14780 | TNF, TRAF5, MAPK14, ATF4, CXCL2, BCL3, MMP9 | More | |
| Carvedilol | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | |
| Carvedilol | hsa04720 | Long-term potentiation | 2.85E-02 | 3 | P16298, P51812, Q02750 | PPP3CB, RPS6KA3, MAP2K1 | More | |
| Carvedilol | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | |
| Carvedilol | hsa04723 | Retrograde endocannabinoid signaling | 4.48E-02 | 2 | Q08828, O95298 | ADCY1, NDUFC2 | More | |
| Carvedilol | hsa04730 | Long-term depression | 3.52E-02 | 1 | Q14344 | GNA13 | More | |
| Carvedilol | hsa04740 | Olfactory transduction | 2.52E-02 | 1 | Q9H255 | OR51E2 | More | |
| Carvedilol | hsa04742 | Taste transduction | 1.01E-02 | 1 | P30939 | HTR1F | More | |
| Carvedilol | hsa04750 | Inflammatory mediator regulation of TRP channels | 3.72E-02 | 3 | P14778, P42338, P24723 | IL1R1, PIK3CB, PRKCH | More | |
| Carvedilol | hsa04910 | Insulin signaling pathway | 2.35E-02 | 3 | P22694, P06737, P49841 | PRKACB, PYGL, GSK3B | More | |
| Carvedilol | hsa04913 | Ovarian steroidogenesis | 2.54E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | |
| Carvedilol | hsa04914 | Progesterone-mediated oocyte maturation | 1.00E-02 | 4 | Q17RY0, Q9Y6D9, P51812, Q02750 | CPEB4, MAD1L1, RPS6KA3, MAP2K1 | More | |
| Carvedilol | hsa04919 | Thyroid hormone signaling pathway | 7.11E-03 | 4 | P49841, P22694, O60244, Q9NVC6 | GSK3B, PRKACB, MED14, MED17 | More | |
| Carvedilol | hsa04924 | Renin secretion | 4.04E-02 | 2 | P22694, P07550 | PRKACB, ADRB2 | More | |
| Carvedilol | hsa04926 | Relaxin signaling pathway | 2.41E-02 | 4 | P18848, P22694, P14780, P30679 | ATF4, PRKACB, MMP9, GNA15 | More | |
| Carvedilol | hsa04927 | Cortisol synthesis and secretion | 2.54E-02 | 2 | P18848, P22694 | ATF4, PRKACB | More | |
| Carvedilol | hsa04929 | GnRH secretion | 3.63E-02 | 2 | P42338, P49407 | PIK3CB, ARRB1 | More | |
| Carvedilol | hsa04931 | Insulin resistance | 1.94E-02 | 3 | P01375, P49841, P06737 | TNF, GSK3B, PYGL | More | |
| Carvedilol | hsa04932 | Non-alcoholic fatty liver disease | 2.44E-03 | 5 | P01375, P49841, P48023, Q16718, O14521 | TNF, GSK3B, FASLG, NDUFA5, SDHD | More | |
| Carvedilol | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
| Carvedilol | hsa04960 | Aldosterone-regulated sodium reabsorption | 4.38E-02 | 1 | P48048 | KCNJ1 | More | |
| Carvedilol | hsa04970 | Salivary secretion | 1.91E-02 | 3 | P07550, P22694, P49913 | ADRB2, PRKACB, CAMP | More | |
| Carvedilol | hsa04973 | Carbohydrate digestion and absorption | 4.12E-03 | 2 | O43451, P42338 | MGAM, PIK3CB | More | |
| Carvedilol | hsa04976 | Bile secretion | 8.77E-05 | 5 | O43315, Q08828, P22694, P08183, Q14032 | AQP9, ADCY1, PRKACB, ABCB1, BAAT | More | |
| Carvedilol | hsa04979 | Cholesterol metabolism | 9.14E-03 | 2 | P38571, P61916 | LIPA, NPC2 | More | |
| Carvedilol | hsa05010 | Alzheimer disease | 3.57E-02 | 4 | O95298, Q00535, O75460, P28070 | NDUFC2, CDK5, ERN1, PSMB4 | More | |
| Carvedilol | hsa05014 | Amyotrophic lateral sclerosis | 3.57E-02 | 4 | O95298, O75460, P28070, Q8TEV9 | NDUFC2, ERN1, PSMB4, SMCR8 | More | |
| Carvedilol | hsa05020 | Prion disease | 3.80E-02 | 4 | Q16718, O14521, P49841, Q16539 | NDUFA5, SDHD, GSK3B, MAPK14 | More | |
| Carvedilol | hsa05022 | Pathways of neurodegeneration - multiple diseases | 2.00E-04 | 13 | P49841, Q16718, O95298, O14521, Q06055, Q8TEV9, O75460, Q13561, Q16539, Q00535, Q08752, O15020, P28070 | GSK3B, NDUFA5, NDUFC2, SDHD, ATP5G2, SMCR8, ERN1, DCTN2, MAPK14, CDK5, PPID, SPTBN2, PSMB4 | More | |
| Carvedilol | hsa05031 | Amphetamine addiction | 4.32E-02 | 3 | P22694, P18848, Q13547 | PRKACB, ATF4, HDAC1 | More | |
| Carvedilol | hsa05034 | Alcoholism | 2.10E-03 | 4 | Q13547, P58876, Q16778, O60814 | HDAC1, H2BC5, HIST2H2BE, H2BC12 | More | |
| Carvedilol | hsa05100 | Bacterial invasion of epithelial cells | 2.85E-02 | 3 | Q14141, Q05397, Q96JJ3 | SEPT6, PTK2, ELMO2 | More | |
| Carvedilol | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 2.27E-02 | 4 | Q16539, P09341, P25024, P25025 | MAPK14, CXCL1, CXCR1, CXCR2 | More | |
| Carvedilol | hsa05135 | Yersinia infection | 3.29E-02 | 4 | Q05397, P51812, Q02750, Q96JJ3 | PTK2, RPS6KA3, MAP2K1, ELMO2 | More | |
| Carvedilol | hsa05140 | Leishmaniasis | 2.47E-02 | 5 | P13612, O75015, P01375, P49006, Q16539 | ITGA4, FCGR3B, TNF, MARCKSL1, MAPK14 | More | |
| Carvedilol | hsa05143 | African trypanosomiasis | 2.72E-02 | 2 | P01375, P48023 | TNF, FASLG | More | |
| Carvedilol | hsa05144 | Malaria | 1.91E-02 | 3 | P01375, P35443, P26718 | TNF, THBS4, KLRK1 | More | |
| Carvedilol | hsa05146 | Amoebiasis | 3.03E-03 | 8 | P09341, P19875, P14778, P27930, P01375, P05089, P30679, P22694 | CXCL1, CXCL2, IL1R1, IL1R2, TNF, ARG1, GNA15, PRKACB | More | |
| Carvedilol | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | |
| Carvedilol | hsa05163 | Human cytomegalovirus infection | 2.72E-03 | 7 | P01375, P50151, P49841, P14778, P25025, Q16539, O00463 | TNF, GNG10, GSK3B, IL1R1, CXCR2, MAPK14, TRAF5 | More | |
| Carvedilol | hsa05202 | Transcriptional misregulation in cancer | 1.24E-02 | 4 | P27930, P11215, Q13547, P12980 | IL1R2, ITGAM, HDAC1, LYL1 | More | |
| Carvedilol | hsa05203 | Viral carcinogenesis | 6.44E-03 | 4 | Q13547, P58876, Q16778, O60814 | HDAC1, H2BC5, HIST2H2BE, H2BC12 | More | |
| Carvedilol | hsa05205 | Proteoglycans in cancer | 3.68E-02 | 5 | P14780, P01375, P23588, Q13635, P22694 | MMP9, TNF, EIF4B, PTCH1, PRKACB | More | |
| Carvedilol | hsa05225 | Hepatocellular carcinoma | 1.85E-02 | 2 | Q92529, P51531 | SHC3, SMARCA2 | More | |
| Carvedilol | hsa05321 | Inflammatory bowel disease | 1.91E-02 | 3 | P01375, Q14765, Q9UL17 | TNF, STAT4, TBX21 | More | |
| Carvedilol | hsa05322 | Systemic lupus erythematosus | 1.18E-02 | 3 | P58876, Q16778, O60814 | H2BC5, HIST2H2BE, H2BC12 | More | |
| Carvedilol | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
| Carvedilol | hsa05332 | Graft-versus-host disease | 7.27E-04 | 4 | P48023, P01375, P26715, Q13241 | FASLG, TNF, KLRC1, KLRD1 | More | |
| Carvedilol | hsa05415 | Diabetic cardiomyopathy | 1.28E-02 | 4 | Q16718, O14521, Q16539, P49841 | NDUFA5, SDHD, MAPK14, GSK3B | More | |
| Carvedilol | hsa05418 | Fluid shear stress and atherosclerosis | 1.29E-05 | 8 | Q16539, P42338, Q14145, P10599, P14780, P01375, P14778, P27930 | MAPK14, PIK3CB, KEAP1, TXN, MMP9, TNF, IL1R1, IL1R2 | More | |
